IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
PIPPHARMACON & IJPR 2018

PIPPHARMACON & IJPR 2018

Click to download
 

Article Detail

Label
Label
One year follow up of kidney-transplanted patients who received Rabbit anti-thymocyteglobulinis

Author: LEILA MALEKMAKAN, TARANEHTADAYON, ZYNAB KARIMI, ALI ALRASHID
Abstract: Rabbit anti-thymocyteglobulinis (rATG) the most common drug, used for induction therapy in renal transplanted patient. Though, it still has not been approved by FDA. This studyaimed to evaluate the outcome of kidney transplanted patients who received rATG for induction.We gathered data of 54 patients who went under kidney transplantation and received rATG as induction therapy from 2013 till 2016. Also we followed these patients for one year and recorded their outcome. The mean age of patients was 40.2±11.6 and 32 patients (59.3%) were male. Generally, 66.7% (36 patients) of our patients experienced survived graft, 11.1% (6 patients) lost their graft, 3.7% (2 patients) experienced acute rejection and 20.4% (10 patients) of patients died during the study. Dead was occurred more in patients who suffered from both hypertension and diabetes and patients with cardiovascular disease (p=0.045, 0.023). Also graft loss was seen more in patients with re-transplant (p=0.012). Over all 3.8% (2 patients) of our patients developed malignancy. A wide variety of ranges reported for survival, graft loss, acute rejection and deathof patients who received rATG which is mostly due to small number of population. As a result, study with larger population must be done. Also malignancy is a lethal side effect of this drug that more studies must be done to determine the vulnerable patients.
Keyword: ESRD; rATG; Transplant
DOI: https://doi.org/10.31838/ijpr/2019.11.01.021
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
AICTE INTERNATIONAL CONFERENCE

AICTE Sponsored International Conference on Challenges, Opportunities and Newer Directions of Pharmacovigilance and Clinical Research in India

Download Brochure


For More Detail Visit www.pippharmacon.org
News & Events
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477